D. Bixby

D. Bixby, Anthony J. Perissinotti, B. Marini, 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors.

M. Talpaz, D. Bixby, K. Pettit, 2021, Clinical lymphoma, myeloma & leukemia.

Implementation of a Multidisciplinary Care Pathway via an Emergency Department-ICU to Improve Care of Emergency Department Patients Presenting With Leukostasis

B. Bassin, J. Cranford, D. Bixby, 2020, Critical care explorations.

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial

A. Krämer, J. Cortes, K. Yee, 2018, British journal of haematology.

Oncology stewardship in acute myeloid leukemia

D. Bixby, Anthony J. Perissinotti, B. Marini, 2022, Annals of Hematology.

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.

F. Ravandi, D. DeAngelo, J. Lancet, 2018, Blood.

Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosis

D. Bixby, Anthony J. Perissinotti, B. Marini, 2019, Leukemia & lymphoma.

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

J. Cortes, J. Kolitz, R. Stone, 2016 .

Real world outcomes in patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation–A single institution experience

Radhika Takiar, D. Bixby, Anthony J. Perissinotti, 2022, Leukemia research reports.

The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia.

M. Talpaz, I. Maillard, D. Bixby, 2018, Leukemia research.

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

I. Flinn, T. Clackson, H. Kantarjian, 2010 .

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

I. Flinn, H. Kantarjian, F. Haluska, 2011, Cancer Chemotherapy and Pharmacology.

Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival

T. Braun, S. Choi, J. Magenau, 2019, Bone Marrow Transplantation.

FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML

T. Braun, D. Hanauer, S. Choi, 2015, Bone Marrow Transplantation.

Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice

K. Ravi, D. Bixby, Anthony J. Perissinotti, 2021, Leukemia & lymphoma.

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

I. Flinn, T. Clackson, H. Kantarjian, 2013, British journal of haematology.

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

F. Appelbaum, K. Gregory, M. Tallman, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia.

D. Bixby, Anthony J. Perissinotti, J. Nagel, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

J. Cortes, J. Kolitz, R. Stone, 2016 .

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.

J. Cortes, J. Kolitz, J. Lancet, 2021, The Lancet. Haematology.

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

K. Kannan, R. Gregory, M. Levis, 2022, Haematologica.

Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors

O. Frankfurt, N. Daver, J. Altman, 2022, American journal of hematology.

PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia†

D. Bixby, Anthony J. Perissinotti, B. Marini, 2018, Leukemia & lymphoma.

Fibroblast Growth Factor 23–Induced Hypophosphatemia in Acute Leukemia

R. Koenig, D. Bixby, Rachel B. Reinert, 2018, Journal of the Endocrine Society.

Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse/refractory acute myeloid leukemia

D. Bixby, Anthony J. Perissinotti, J. Nagel, 2017, Supportive Care in Cancer.

Clinical Availability of ATRA for Patients With Suspected Acute Promyelocytic Leukemia: Why Guidelines May Not Be Followed.

D. Bixby, Anthony J. Perissinotti, B. Marini, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts.

D. Bixby, Anthony J. Perissinotti, B. Marini, 2021, Leukemia research.

Prevalence of bloodstream infections in neutropenic patients with bacteriuria

C. Chenoweth, D. Bixby, E. Herc, 2017, Infection Control & Hospital Epidemiology.

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

F. Ravandi, D. DeAngelo, J. Lancet, 2015 .

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Robert K. Stuart, Antje Hoering, Arthur C. Louie, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute Myeloid Leukemia , Version 3 . 2019

Donnell, F. Appelbaum, K. Gregory, 2019 .

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

F. Appelbaum, K. Gregory, D. Arber, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy

D. Bixby, Anthony J. Perissinotti, B. Marini, 2019, Open forum infectious diseases.

Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG

M. Talpaz, D. Bixby, Anthony J. Perissinotti, 2018, Annals of Hematology.

NCCN Acute Myeloid Leukemia , Version 3 . 2017 Clinical Practice Guidelines in Oncology

F. Appelbaum, K. Gregory, D. Arber, 2017 .

Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase

J. Auten, D. Bixby, Anthony J. Perissinotti, 2022, Leukemia & lymphoma.

Genomic analysis of adult B-ALL identifies potential markers of shorter survival.

Lauren B. Smith, S. South, J. Gastier-Foster, 2017, Leukemia research.

The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to Mdm2 inhibitor-mediated apoptosis

S. Malek, Shaomeng Wang, D. Bixby, 2008, Cell cycle.

Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy

H. Khoury, D. Bixby, 2015, Leukemia & lymphoma.

Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.

M. Kaminski, Siân Jones, P. Ouillette, 2014, Blood.

Mutations in linker histone genes HIST 1 H 1 B , C , D , and E ; OCT 2 ( POU 2 F 2 ) ; IRF 8 ; and ARID 1 A underlying the pathogenesis of follicular lymphoma

M. Kaminski, Siân Jones, P. Ouillette, 2014 .

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.

P. Ouillette, S. Malek, Shaomeng Wang, 2010, Blood.

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

T. Cluzeau, J. Liesveld, P. Rousselot, 2020 .

Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.

Bo Wen, Jolanta Grembecka, Hongzhi Miao, 2015, Cancer cell.

HIV–1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs

James Riddell, Michael R. Savona, K. Collins, 2010, Nature Medicine.

Catalyzing improvements in ALL therapy with asparaginase.

D. Bixby, Anthony J. Perissinotti, B. Marini, 2017, Blood reviews.

p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells

A. Arbor, S. Malek, Shaomeng Wang, 2011, Leukemia.

Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors.

M. Talpaz, D. Bixby, 2008, Clinical lymphoma & myeloma.

Managing inadequate responses to frontline treatment of chronic myeloid leukemia: a case-based review.

D. Bixby, Dale L Bixby, 2013, Cancer treatment reviews.

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.

F. Appelbaum, K. Gregory, M. Tallman, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells.

S. Morrison, M. Shackleton, K. Collins, 2011, Cell host & microbe.

Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission

T. Braun, S. Mineishi, S. Choi, 2015, Annals of Hematology.

Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

M. Maris, D. DeAngelo, S. Blakemore, 2015, British journal of haematology.

Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.

H. Erba, D. Bixby, Anthony J. Perissinotti, 2019, Clinical lymphoma, myeloma & leukemia.

Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.

J. Cortes, J. Kolitz, J. Lancet, 2020 .

Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia.

K. Kinzler, B. Vogelstein, N. Papadopoulos, 2011, Blood.

The leukemia strikes back: a review of pathogenesis and treatment of secondary AML

D. Bixby, Anthony J. Perissinotti, B. Marini, 2019, Annals of Hematology.

CD4 is expressed on a heterogeneous subset of hematopoietic progenitors, which persistently harbor CXCR4 and CCR5-tropic HIV proviral genomes in vivo

S. Morrison, N. Markowitz, K. Collins, 2017, PLoS pathogens.

Minimizing waste during preparation of blinatumomab infusions.

D. Bixby, Anthony J. Perissinotti, B. Marini, 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.

M. Konopleva, H. Kantarjian, A. Lane, 2022, Blood.

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

F. Ravandi, D. DeAngelo, J. Lancet, 2016 .

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

M. Konopleva, M. Maris, H. Kantarjian, 2016 .

Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction

D. Bixby, Anthony J. Perissinotti, B. Marini, 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

F. Ravandi, D. DeAngelo, J. Lancet, 2016 .

A diagnosis of discernment: Identifying a novel ATRX mutation in myelodysplastic syndrome with acquired α-thalassemia.

Radhika Takiar, D. Ginsburg, S. Choi, 2019, Cancer genetics.

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

J. Carulli, M. McKeown, M. Eaton, 2022, Blood advances.

Impact of number of lumens in central-venous catheters on central-line bloodstream infection (CLABSI) and venous thromboembolism (VTE) risk in patients with acute leukemia

D. Bixby, Anthony J. Perissinotti, B. Marini, 2021, Infection Control & Hospital Epidemiology.

Shared clonal cytogenetic abnormalities in aberrant mast cells and leukemic myeloid blasts detected by single nucleotide polymorphism microarray‐based whole‐genome scanning

J. Frederiksen, C. Ross, Lina Shao, 2016, Genes, chromosomes & cancer.

Efficacy of HMA +/- Venetoclax or Intensive Chemotherapy in Blast-Phase Myeloproliferative Neoplasms

M. Talpaz, D. Bixby, Anthony J. Perissinotti, 2021, Blood.